Mirum Pharmaceuticals (MIRM) SVP sells 1,840 shares under 10b5-1 plan

Rhea-AI Filing Summary

Mirum Pharmaceuticals, Inc. senior vice president and global controller Jolanda Howe sold 1,840 shares of Common Stock on August 3, 2026 at a price of 105.2900 in an open-market or private transaction executed under a Rule 10b5-1 trading plan adopted on March 18, 2026.

After this sale, Howe directly held 1,274.0000 shares of Mirum Common Stock.

Insider Trade Summary 10b5-1

Net Seller: 1,840 shares

Net Sell 1 txn

Insider Howe Jolanda

Role SVP, GLOBAL CONTROLLER

Sold 1,840 shs ($194K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	1,840	$105.29	$194K

Holdings After Transaction: Common Stock — 1,274 shares (Direct)

Footnotes (1)

1. F1. Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 18, 2026.

Key Figures

Shares sold: 1840.0000 shares Sale price per share: 105.2900 Shares owned after transaction: 1274.0000 shares +2 more

5 metrics

Shares sold 1840.0000 shares Common Stock sold by Jolanda Howe on August 3, 2026

Sale price per share 105.2900 Per-share price for the Common Stock sold on August 3, 2026

Shares owned after transaction 1274.0000 shares Direct Common Stock holdings of Jolanda Howe following the sale

10b5-1 plan adoption date March 18, 2026 Date Jolanda Howe adopted the Rule 10b5-1 trading plan used for this sale

Derivative transactions reported 0 Derivative transaction count in this insider report

Key Terms

Rule 10b5-1 Plan, Common Stock, open market or private transaction

3 terms

Rule 10b5-1 Plan regulatory

"Reported transaction occurred pursuant to a Rule 10b5-1 Plan"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

Common Stock financial

"security_title: "Common Stock" for the reported transaction"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

open market or private transaction financial

"transaction_code_description: "Sale in open market or private transaction""

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/05/2026 - 04:27 PM Accepted by SEC EDGAR 08/05/2026 - 04:26 PM Learn about SEC filing dates

FAQ

What insider stock transaction did Mirum Pharmaceuticals (MIRM) disclose for Jolanda Howe?

Mirum Pharmaceuticals executive Jolanda Howe sold 1,840 shares of the company’s Common Stock on August 3, 2026 at 105.2900 per share. The transaction was a sale in an open-market or private transaction executed under a pre-arranged Rule 10b5-1 trading plan.

How many Mirum Pharmaceuticals (MIRM) shares does Jolanda Howe own after the August 2026 sale?

Following the transaction, Jolanda Howe directly held 1,274.0000 shares of Mirum Pharmaceuticals Common Stock. This figure reflects her reported direct ownership immediately after selling 1,840 shares in the Rule 10b5-1 plan trade dated August 3, 2026.

At what price were Mirum Pharmaceuticals (MIRM) shares sold in Jolanda Howe’s August 3, 2026 trade?

The reported shares were sold at a price of 105.2900 per share. This per-share price applies to the entire block of 1,840 Common Stock shares sold by Jolanda Howe in the open-market or private transaction executed on August 3, 2026.

Was Jolanda Howe’s Mirum Pharmaceuticals (MIRM) stock sale made under a Rule 10b5-1 trading plan?

Yes. The transaction occurred pursuant to a Rule 10b5-1 Plan adopted by Jolanda Howe on March 18, 2026. This indicates the trade was pre-arranged under a written trading plan rather than initiated at the time of the August 3, 2026 sale.

What is Jolanda Howe’s position at Mirum Pharmaceuticals (MIRM) in relation to this stock sale?

Jolanda Howe serves as SVP, GLOBAL CONTROLLER at Mirum Pharmaceuticals. Her role as a senior officer makes this 1,840-share Common Stock sale, and the remaining 1,274.0000 shares she directly owns, subject to public reporting as an insider transaction.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Howe Jolanda

(Last) (First) (Middle)

C/O MIRUM PHARMACEUTICALS, INC.

989 E HILLSDALE BLVD., SUITE 300

(Street)

FOSTER CITY CALIFORNIA 94404

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Mirum Pharmaceuticals, Inc. [ MIRM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, GLOBAL CONTROLLER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/03/2026		S(1)		1,840	D	$105.29	1,274	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 18, 2026.

	/s/ Judit Ryvkin, Attorney-in-Fact	08/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)